Reconnecting

The current page stays visible while onset.to reconnects in the background.

DEA proposes a 57-fold increase in the 2027 ibogaine production ceiling, but the quota does not establish supply

Open original

The DEA has proposed raising the 2027 national ibogaine production ceiling from 210 to 12,002 grams, roughly 57-fold, and increasing the MDMA quota from 12,000 to 33,296 grams. It cites increased research and clinical trials as the reason for both changes. The proposal also raises psilocybin and psilocyn quotas without explaining why. A national ceiling is not evidence of actual production or clinical supply: manufacturers also need substance-specific registration and individual quotas, while imports require separate permits. The public record mainly shows ibogaine registration applications and an unverified company account of an individual quota. The FDA has approved no ibogaine product, and the proposed figures could change before a final order. Comments close December 10.